Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

109
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
109
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

77
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
77
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

113
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
113
Pharmacogenetics and Pharmacogenomics: Overview01:29

Pharmacogenetics and Pharmacogenomics: Overview

144
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
144
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

158
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
158
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

68
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
68

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Combined DMT-harmine formulation reduces negative self-referential emotions during social self-evaluation: a randomized placebo-controlled trial in healthy volunteers.

Psychopharmacology·2026
Same author

Modelling the effect of V1a receptor antagonism and its potential therapeutic effect in circadian disorders.

Npj biological timing and sleep·2026
Same author

Leveraging the Metabolic Fingerprint of Sleep Deprivation and Sleep Restriction for Forensic Applications: A Machine Learning Study in Oral Fluid Metabolomics.

Journal of proteome research·2026
Same author

Brain Health from Sleep EEG: A Multicohort, Deep Learning Biomarker for Cognition, Disease, and Mortality.

NEJM AI·2026
Same author

Welcome Journal of Sleep Research.

Journal of sleep research·2026
Same author

Farewell to Dieter Riemann-Gratitude of the ESRS.

Journal of sleep research·2026

Related Experiment Video

Updated: Mar 30, 2026

Optogenetic Manipulation of Neural Circuits During Monitoring Sleep/wakefulness States in Mice
08:58

Optogenetic Manipulation of Neural Circuits During Monitoring Sleep/wakefulness States in Mice

Published on: June 19, 2019

10.7K

Sleep Pharmacogenetics: Personalized Sleep-Wake Therapy.

Sebastian C Holst1, Amandine Valomon1, Hans-Peter Landolt1

  • 1Institute of Pharmacology and Toxicology and Zürich Center for Interdisciplinary Sleep Research, University of Zürich, CH-8057 Zürich, Switzerland;

Annual Review of Pharmacology and Toxicology
|November 4, 2015
PubMed
Summary

Genetic variations impact how individuals respond to sleep medications targeting key brain chemicals. Understanding these genetic factors is crucial for developing personalized sleep disorder treatments.

Keywords:
GABAH3 receptorNREM sleepREM sleepcaffeinecircadiangenotype-phenotypemelatoninorexinpharmacodynamicspharmacokineticspolymorphism

More Related Videos

A High-performance Liquid Chromatography Measurement of Kynurenine and Kynurenic Acid: Relating Biochemistry to Cognition and Sleep in Rats
07:04

A High-performance Liquid Chromatography Measurement of Kynurenine and Kynurenic Acid: Relating Biochemistry to Cognition and Sleep in Rats

Published on: August 19, 2018

11.1K
Author Spotlight: Overcoming Challenges in Drosophila Sleep Measurement Using DAM System
05:59

Author Spotlight: Overcoming Challenges in Drosophila Sleep Measurement Using DAM System

Published on: October 20, 2023

3.3K

Related Experiment Videos

Last Updated: Mar 30, 2026

Optogenetic Manipulation of Neural Circuits During Monitoring Sleep/wakefulness States in Mice
08:58

Optogenetic Manipulation of Neural Circuits During Monitoring Sleep/wakefulness States in Mice

Published on: June 19, 2019

10.7K
A High-performance Liquid Chromatography Measurement of Kynurenine and Kynurenic Acid: Relating Biochemistry to Cognition and Sleep in Rats
07:04

A High-performance Liquid Chromatography Measurement of Kynurenine and Kynurenic Acid: Relating Biochemistry to Cognition and Sleep in Rats

Published on: August 19, 2018

11.1K
Author Spotlight: Overcoming Challenges in Drosophila Sleep Measurement Using DAM System
05:59

Author Spotlight: Overcoming Challenges in Drosophila Sleep Measurement Using DAM System

Published on: October 20, 2023

3.3K

Area of Science:

  • Neuroscience
  • Pharmacology
  • Genetics

Background:

  • Key neurotransmitters and neuromodulators (dopamine, serotonin, acetylcholine, etc.) regulate sleep-wake cycles.
  • Dysregulation of these neurochemical systems causes sleep-wake disorders.
  • Current treatments are often symptomatic, with variable efficacy and side effects influenced by genetics.

Purpose of the Study:

  • To review the impact of genetic variants on drug response for sleep-wake regulation.
  • To explore opportunities for personalized medicine in sleep disorder treatment.
  • To identify strategies for developing evidence-based, tailored sleep therapeutics.

Main Methods:

  • Review of existing research on genetic variants affecting drug exposure and sensitivity.
  • Analysis of functional polymorphisms influencing sleep-related drug response phenotypes.
  • Consideration of animal models and pharmacogenomic investigations.

Main Results:

  • Numerous genetic polymorphisms significantly modify individual responses to sleep medications.
  • These variations highlight the genetic basis for variable therapeutic and adverse effects.
  • The neurochemistry of sleep-wake regulation is a target for pharmacogenetic interventions.

Conclusions:

  • Personalized sleep-wake therapy requires integrating pharmacogenetics with pharmacogenomic studies.
  • Further research into gene-specific drug actions and epigenetic mechanisms is needed.
  • This approach promises safer and more effective treatments for a growing number of sleep disorder patients.